This study was conducted to evaluate the efficacy of Dexrazoxane (ICRF-187) as a cardioprotective agent in pediatric and young adult osteosarcoma patients receiving chemotherapy containing a high cumulative dose of doxorubicin reaching 600 mg/m2. Another objective was to determine the relationship between serum levels of cardiac Troponin-I (cTnI) and possible acute cardiac injury resulting from the high cumulative dose of doxorubicin used. The study group was evaluated for incidence and degree of cardiotoxicity and response rates to four cycles of pre-operative chemotherapy.